Methods and systems for toxin delivery to the nasal cavity

Patent metadata

Field	Value
Publication number	US-10052465-B2
Application number	US-201715615344-A
Country	US
Kind code	B2
Filing date	Jun 6, 2017
Priority date	Jul 22, 2005
Publication date	Aug 21, 2018
Grant date	Aug 21, 2018

Abstract

Methods and systems for delivering toxin and toxin fragments to a patient's nasal cavity provide for both release of the toxin and delivery of energy which selectively porates target cells to enhance uptake of the toxin. The use of energy-mediated delivery is particularly advantageous with light chain fragment toxins which lack cell binding capacity.

First claim

What is claimed is:

1. A system for treating a nasal condition in a patient, said system comprising:
an apparatus comprising an applicator tip and insertable into a nasal cavity of the patient, the applicator tip comprising an outer expandable member and an inner expandable member disposed within the outer expandable member and configured to expand within the nasal cavity, wherein expansion of the inner expandable member causes expansion of the outer expandable member such that the outer expandable member is placed in contact with a wall of the nasal cavity; and
a toxin either: (i) carried by the outer expandable member or (ii) disposed in a space between the outer and inner expandable members, and
wherein the outer expandable member is configured to deliver the toxin to target cells in the wall of the nasal cavity.

2. The system of claim 1 , wherein the toxin comprises a light chain fragment of a neurotoxin substantially free of heavy chain fragments of the neurotoxin.

3. The system of claim 2 , wherein the neurotoxin consists of botulinum toxin.

4. The system of claim 3 , wherein the light chain fragment is derived from at least one of botulinum toxins A, B, C, D, E, F, and G.

5. The system of claim 1 , wherein the toxin comprises at least one of: a liquid, gel, foam, cream, lotion, or lyophilized compound.

6. The system of claim 1 , wherein the inner expandable member comprises a low volume configuration adapted to facilitate insertion into the nasal cavity and an expanded volume configuration adapted to place the outer expandable member in contact with the wall of the nasal cavity.

7. The system of claim 1 , wherein the expansion of the inner expandable member facilitates delivery of the toxin from the outer expandable member.

8. The system of claim 1 , further comprising an impermeable lining separating the inner expandable member and the outer expandable member and configured to prevent the toxin from entering the inner member.

9. The system of claim 1 , wherein the outer expandable member comprises an outer balloon and the toxin is delivered through one or more pores of the outer balloon.

10. The system of claim 9 , wherein the inner expandable member comprises an inner balloon.

11. The system of claim 10 , further comprising a fluid introduced into the inner balloon to expand the inner expandable member.

12. The system of claim 9 , wherein the inner expandable member comprises a wire, frame, or scaffold.

13. The system of claim 1 , wherein the outer expandable member comprises a sponge.

14. The system of claim 13 , wherein the inner expandable member comprises a spring element.

15. The system of claim 1 , wherein the outer expandable member comprises at least one of: a mesh pad, porous polymer, bioresorbable coating, or muco-adhesive surface.

16. The system of claim 1 , further comprising an energy applicator configured for applying energy to the target cells to enhance delivery of the toxin to the target cells.

17. The system of claim 16 , wherein the energy is applied to the target cells under conditions which cause poration of cell membranes of the target cells.

18. The system of claim 17 , wherein the energy applicator is adapted to apply energy comprising at least one of: electrical pulses, acoustic pulses, x-ray energy, or microwave energy.

19. The system of claim 1 , wherein the outer expandable member comprises a porous portion and a non-porous portion.

20. The system of claim 19 , wherein the outer expandable member is configured to deliver the toxin from the porous portion to target cells in the wall of the nasal cavity.

21. An apparatus for treating a nasal condition in a patient, said apparatus comprising:
an applicator tip comprising an outer expandable member and an inner expandable member,
wherein the applicator tip is configured to be inserted into a nasal cavity of the patient,
wherein the inner expandable member is disposed within the outer expandable member and configured to expand within the nasal cavity,
wherein expansion of the inner expandable member causes expansion of the outer expandable member such that the outer expandable member is placed in contact with a wall of the nasal cavity,
wherein (i) the outer expandable member is configured to carry a toxin or (ii) the applicator tip comprises a space between the outer expandable member and the inner expandable member which is configured to carry the toxin, and
wherein the outer expandable member in configured to deliver the toxin to target cells in the wall of the nasal cavity.

22. The apparatus of claim 21 , wherein the inner expandable member comprises a low volume configuration adapted to facilitate insertion into the nasal cavity and an expanded volume configuration adapted to place the outer expandable member in contact with the wall of the nasal cavity.

23. The apparatus of claim 21 , wherein the expansion of the inner expandable member facilitates delivery of the toxin from the outer expandable member.

24. The apparatus of claim 21 , further comprising an impermeable lining separating the inner expandable member and the outer expandable member and configured to prevent the toxin from entering the inner member.

25. The apparatus of claim 21 , wherein the outer expandable member comprises an outer balloon and the toxin is delivered through one or more pores of the outer balloon.

26. The apparatus of claim 25 , wherein the inner expandable member comprises an inner balloon.

27. The apparatus of claim 25 , wherein the inner expandable member comprises a wire, frame, or scaffold.

28. The apparatus of claim 21 , wherein the outer expandable member comprises a sponge.

29. The apparatus of claim 28 , wherein the inner expandable member comprises a spring element.

30. The apparatus of claim 21 , wherein the outer expandable member comprises at least one of: a mesh pad, porous polymer, bioresorbable coating, or muco-adhesive surface.

31. The apparatus of claim 21 , further comprising an energy applicator configured for applying energy to the target cells to enhance delivery of the toxin to the target cells.

32. The apparatus of claim 31 , wherein the energy is applied to the target cells under conditions which cause poration of cell membranes of the target cells.

33. The apparatus of claim 32 , wherein the energy applicator is adapted to apply energy comprising at least one of: electrical pulses, acoustic pulses, x-ray energy, or microwave energy.

34. The apparatus of claim 21 , wherein the outer expandable member comprises a porous portion and a non-porous portion.

35. The apparatus of claim 34 , wherein the outer expandable member is configured to deliver the toxin from the porous portion to target cells in the wall of the nasal cavity.

Assignees

• Foundry Llc

Inventors

• Deem Mark E
• Gifford Hanson

Classifications

• A61M25/0084

  being one or more injection needles · CPC title

• A61N1/0546

  Nasal electrodes · CPC title

• A61K38/4893

  Botulinum neurotoxin (3.4.24.69) · CPC title

• A61M2210/0618

  Nose · CPC title

• A61M31/00 Primary

  Devices for introducing or retaining media, e.g. remedies, in cavities of the body (A61M25/00 takes precedence {; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008}) · CPC title